APLS Apellis Pharmaceuticals, Inc.
APLS Apellis Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
APLS Price Structure
Loading chart…
Loading timeframes…
Reported the quarter ending 2026-03-31: revenue $268M, diluted EPS $0.15, net income $19M (the desk's provider cache). Across the print the stock moved -0.2% (close before → first close after).
full note →News (last pull)
Headlines about APLS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 67 days ago · Jun 12
- Apellis Pharmaceuticals Earnings Dates, Reports, Calls 2016-2026 (NASDAQ: APLS) | WallStreetZen
- Apellis Pharmaceuticals (APLS) Earnings Report & Financial Results - Quarterly & Annual ...
- Apellis Pharmaceuticals (APLS) Earnings: Latest Report, Earnings Call & Financials
- Apellis Pharmaceuticals (APLS) Stock Forecast for 2026, 2030-2040
- Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics ...
APLS research tape
4 dated scans, research, and events, newest first — the full record.